As such, it is a therapeutic option for tumors with high ICOS in Tregs but low ICOS in effectors and tumors in which ICOS is a tumor-associated antigen.30,31 It is likely contraindicated in tumors with higher ICOS expression in effector than Treg cells. The gene discussed is ICOS; the disease is neoplasm.